Physician profile
John Carey
NPI 1770578924
$2,039.32
in general payments reported to CMS, 2019-2025
20 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $146 · 2021: $73.63 · 2022: $242 · 2023: $493 · 2024: $611 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.38 | 2019-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $175.22 | 2019-2024 | Ilumya |
| Janssen Biotech, INC. | $155.50 | 2020-2025 | Simponi, Remicade, Stelara |
| Revance Therapeutics, INC. | $153.04 | 2024 | Daxxify |
| Incyte Corporation | $152.98 | 2023-2024 | Opzelura |
| Lilly USA, LLC | $115.04 | 2020-2025 | Olumiant, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $101.03 | 2019-2025 | Nemluvio |
| Allergan, INC. | $49.35 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $45.12 | 2023-2025 | |
| Organon LLC | $42.88 | 2023-2025 | Hadlima, Vtama |
| Dermira, INC. | $34.66 | 2019-2020 | |
| Amgen INC. | $30.87 | 2024 | Otezla |
| Pfizer INC. | $28.78 | 2022-2023 | |
| Vyne Pharmaceuticals INC. | $23.44 | 2020 | |
| Genzyme Corporation | $20.00 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $18.80 | 2023 | Adbry |
| Ucb, INC. | $17.35 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.63 | 2025 | Dupixent |
| Helsinn Therapeutics (U.S.), INC. | $15.99 | 2022 | |
| Celgene Corporation | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.